Evidence map›Paper›PMID 34163252›Full record

ArticleClinical epidemiology2021

The Danish Myelodysplastic Syndromes Database: Patient Characteristics and Validity of Data Records.

Tine Bichel Lauritsen, Jan Maxwell Nørgaard, Kirsten Grønbæk, Anders Pommer Vallentin, Syed Azhar Ahmad, Louise Hur Hannig, Marianne Tang Severinsen, Kasper Adelborg, Lene Sofie Granfeldt Østgård

Open access · goldAbstract read
In one paragraph

Article in Clinical epidemiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Tine Bichel LauritsenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-1730-8533
Jan Maxwell NørgaardDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-3592-118X
Kirsten GrønbækDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Anders Pommer VallentinZealand University Hospital, Roskilde, Denmark.
Syed Azhar AhmadDepartment of Hematology, Herlev Hospital, Herlev, Denmark.
Louise Hur HannigDepartment of Hematology, Vejle Hospital, Vejle, Denmark.
Marianne Tang SeverinsenDepartment of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.ORCID 0000-0003-0996-1812
Kasper AdelborgDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Lene Sofie Granfeldt ØstgårdDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Aarhus University Hospital · DKAalborg University Hospital · DKHerlev Hospital · DKOdense University Hospital · DKUniversity of Copenhagen · DKVejle Sygehus · DKZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Danish Myelodysplastic Syndromes Database (DMDSD) comprises nearly all patients diagnosed with myelodysplastic syndromes (MDS) in Denmark since 2010. The DMDSD has not yet been used for epidemiological research and the quality of registered variables remains to be investigated.

objectiveTo describe characteristics of the patients registered in the DMDSD and to calculate predictive values and the proportion of missing values of registered data records.

methodsWe performed a nationwide cross-sectional validation study of recorded disease and treatment data on MDS patients during 2010-2019. Patient characteristics and the proportion of missing values were tabulated. A random sample of 12% was drawn to calculate predictive values with 95% confidence intervals (CIs) of 48 variables using information from medical records as a reference standard.

resultsOverall, 2284 patients were identified (median age: 76 years, men 62%). Of these, 10% had therapy-related MDS, and 6% had an antecedent hematological disease. Hemoglobin level was less than 6.2 mmol/L for 59% of patients. Within the first two years of treatment, 59% received transfusions, 35% received erythropoiesis-stimulating agents, and 15% were treated with a hypomethylating agent. For the majority of variables (around 80%), there were no missing data. A total of 260 medical records were available for validation. The positive predictive value of the MDS diagnosis was 92% (95% CI: 88-95). Predictive values ranged from 64% to 100% and exceeded 90% for 36 out of 48 variables. Stratification by year of diagnosis suggested that the positive predictive value of the MDS diagnosis improved from 88% before 2015 to 95% after.

conclusionIn this study, there was a high accuracy of recorded data and a low proportion of missing data. Thus, the DMDSD serves as a valuable data source for future epidemiological studies on MDS.

Indexed as

accuracycohortdatabasemyelodysplastic syndromesvalidation

Identifiers

PMID34163252
PMCPMC8213953
OpenAlexW3173024505

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.